SCHEMBL632551

SCHEMBL632551

Cc1cccc(NC(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.56
KCNH3 Q9ULD8 1/20 0.56
POLB P06746 1/20 0.54
MAPT P10636 3/20 0.54
CYP3A4 P08684 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
CYP1A2 P05177 2/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
HTT P42858 1/20 0.54
HSD17B10 Q99714 2/20 0.53
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
RECQL P46063 1/20 0.48
ATM Q13315 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31174454 1.00 TDP1 (0.56) TDP1KCNH3POLBMAPTCYP3A4
SCHEMBL9313156 0.85 TDP1 (0.67) TDP1KCNH3POLBMAPTCYP3A4
SCHEMBL10996019 0.83 MAPT (0.50) KCNH3POLBMAPTCYP3A4NPSR1
SCHEMBL1004460 0.83 MAPT (0.50) KCNH3POLBMAPTCYP3A4NPSR1
SCHEMBL28679508 0.80 MAPT (0.52) KCNH3POLBMAPTCYP3A4NPSR1
SCHEMBL27560495 0.80 MAPT (0.52) MAPTCYP3A4NPSR1CYP1A2CYP2D6
SCHEMBL19914819 0.79 MAPT (0.47) KCNH3POLBMAPTCYP3A4NPSR1
SCHEMBL7025738 0.79 CYP3A4 (0.57) TDP1KCNH3POLBMAPTCYP3A4
SCHEMBL11526055 0.79 MAPT (0.50) KCNH3POLBMAPTCYP3A4NPSR1
SCHEMBL11310422 0.79 MAPT (0.47) KCNH3POLBMAPTCYP3A4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007016190-A2 ANTIPARKINSONIAN ACTION OF PHENYLISOPROPYLAMINES DUKE UNIVERSITY (US) 2007-02-08 WO claimed
US-20070027208-A1 Antiparkinsonian Action of Phenylisopropylamines NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-02-01 US claimed
JP-59167545-A None JP disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 US disclosed
CN-114667167-B Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-12-20 CN disclosed
WO-2024215870-A2 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POLYMERASE THETA AND METHODS OF USE THEREOF 1CBIO, INC. (US) 2024-10-17 WO disclosed
EP-4010080-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2023-09-27 EP disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed
WO-2023144793-A1 POL THETA INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-08-03 WO disclosed
WO-2023144793-A1 POL THETA INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-08-03 WO disclosed
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-08-03 US disclosed
US-5929235-A Aromatic tertiary amine compound having benzazepine structures FUJI PHOTO FILM CO., LTD. (JP) 1999-07-27 US disclosed
US-5001263-A Formation of ortho-alkylated aromatic amines from N-alkylated aromatic amines AIR PRODUCTS AND CHEMICALS, INC. (US) 1991-03-19 US disclosed
EP-0066325-B1 PROCESS FOR THE PREPARATION OF ANILINE DERIVATIVES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1985-07-17 EP disclosed
JP-S59167545-A PRODUCTION OF 3-METHYL-4-ISOPROPYLANILINE NIPPON KAYAKU CO LTD 1984-09-21 JP disclosed
EP-0066325-A1 Process for the preparation of aniline derivatives SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1982-12-08 EP disclosed
EP-0018576-B1 PROCESS FOR THE PREPARATION OF N-ALKYLATED AROMATIC AMINES BAYER AG (DE) 1982-04-28 EP disclosed
US-4322492-A Process for the development of color photographic images with p-dialkylaminoaniline color developers AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1982-03-30 US disclosed
US-4268458-A Process for the preparation of N-alkylated aromatic amines BAYER AKTIENGESELLSCHAFT (DE) 1981-05-19 US disclosed
EP-0018576-A1 Process for the preparation of N-alkylated aromatic amines BAYER AG (DE) 1980-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027208-A1 Antiparkinsonian Action of Phenylisopropylamines PNMT, SNCA, COMT TDP1 716/4885KCNH3 479/4885POLB 1486/4885
US-20230242503-A9 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER SDHA, SDHB, NQO1 TDP1 1437/4885KCNH3 4089/4885POLB 356/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 TDP1 1025/4885KCNH3 4412/4885POLB 1778/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 TDP1 1207/4885KCNH3 3987/4885POLB 459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.